Braveheart Investment Group PLC - technology investor - Chief Executive Trevor Brown buys 425,000 shares at 4.04 pence, worth GBP17,165, on Friday. Brown now has 16.2 million shares, a 25.5% stake. Read More
(Alliance News) - Braveheart Investment Group PLC on Tuesday said it has reached profitability in the first six months of its 2024 financial year, as it returns to a positive fair value of investments. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price". Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in the past week and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Braveheart Investment Group PLC - Dodworth, England-based investment company - In the financial year to March 31 swings to pretax loss of GBP8.2 million from profit of GBP2.4 million a year prior. This includes an impairment charge of GBP4.9 million on investments compared with nil in the prior year. Also takes impairment charge of loans in investment companies of GBP1.6 million compared with nil before. Loss per share is 11.38 pence compared with earnings per share of 2.68p. During the year Braveheart wrote down the investments in Paraytec Ltd and Kirkstall Ltd. Believes that, with time, Paraytec and Kirkstall could have the potential to increase in value and thereby provide exit opportunities. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Braveheart Investment Group PLC - Dodworth, England-based investment company - Between Monday and Tuesday, buys a further 4.0 million shares in Autins Group PLC at an average price of 8 pence per share, for a total of GBP320,000. Following this, now holds 23% of the issued share capital of Autins. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Braveheart Investment Group PLC - Dodworth, England-based investment company - Announces conditional sale of Phasefocus Holdings Ltd to analytics instrumentation company Bruker UK Ltd for GBP5 million. Once closing conditions are satisfied, Braveheart expects completion of the sale to occur in the first quarter of 2024. Consideration will be payable in cash and represent GBP17.74 per Phasefocus share. Braveheart currently holds 48.3% of Phasefocus's issued share capital. Estimates that it will receive total sale proceeds of approximately GBP2.1 million after expenses. Braveheart says board is still considering whether to use proceeds to continue support further investments in technology-based companies, or whether to redistribute the proceeds via a special dividend. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Braveheart Investment Group PLC on Wednesday said its wholly-owned portfolio company Paraytec Ltd has secured its first commercial sales contract for the CX300 Optical Particle detector instrument. Read More
Braveheart Investment Group PLC - Dodworth, England-based investment company - Investee company Paraytec Ltd updates on its work in the development of potential use cases for its rapid test instrument, CX300. Explains it has been successfully tested in the detection of adeno-associated viruses, which are used in gene therapy. Notes this is important because virus-like particles such as adeno-associated viruses are used to encapsulate the new gene and deliver it into the body. Points out the target is to market the CX300 for use by all gene therapy manufacturers for in-process assessment of the quality of their adeno-associated virus products during research, development and, in due course, manufacturing. Read More
Braveheart Investment Group PLC - Dodworth, England-based investment company - Updates on Kirkstall Ltd, a company within its investment portfolio. Says Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy & Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford, has developed an "organ on a chip" model of a milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer. Explains this is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated. Read More